Satsuma Pharmaceuticals, Inc. (STSA)

NASDAQ: STSA · IEX Real-Time Price · USD
5.75
-0.13 (-2.21%)
Aug 16, 2022 11:01 AM EDT - Market open
-2.21%
Market Cap 181.63M
Revenue (ttm) n/a
Net Income (ttm) -60.67M
Shares Out 31.59M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,158
Open 5.89
Previous Close 5.88
Day's Range 5.66 - 5.90
52-Week Range 2.51 - 6.52
Beta 0.71
Analysts Buy
Price Target 11.22 (+95.1%)
Earnings Date Aug 8, 2022

About STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. [Read more...]

Industry Pharmaceuticals
IPO Date Sep 13, 2019
CEO John Kollins
Employees 25
Stock Exchange NASDAQ
Ticker Symbol STSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for STSA stock is "Buy." The 12-month stock price forecast is 11.22, which is an increase of 95.13% from the latest price.

Price Target
$11.22
(95.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Does Satsuma Pharmaceuticals (STSA) Have the Potential to Rally 90% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 90% in Satsuma Pharmaceuticals (STSA). While the effectiveness of this highly sought-after metric is questionable...

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects -

Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the...

- More than 1,400 subjects randomized - -  Satsuma expects to announce topline SUMMIT trial results in Q4 2022 -

Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's 64th An...

Oral Presentation: Initial Data from ASCEND Study Highlights STS101's Long-Term Safety and Tolerability Oral Presentation: Initial Data from ASCEND Study Highlights STS101's Long-Term Safety and Tolerab...

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Thursday, June 16th @ 10:30 a.m. ET Thursday, June 16th @ 10:30 a.m. ET

Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal po...

Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 -

Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 -

Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annua...

SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal ...

Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 -

Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors

DELRAY BEACH, Fla., Nov. 9, 2021 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today ann...

Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal ...

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal ...

Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights

- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-

Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acu...

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum

SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal p...

Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS...

- All three dose strengths of STS101, administered with improved 2 nd -generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile -

Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-

Why Earnings Season Could Be Great for Satsuma Pharmaceuticals (STSA)

Satsuma Pharmaceuticals (STSA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022

Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) will conduct a new Phase 3 efficacy trial for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine. The study will start in ...

Satsuma Pharmaceuticals Announces Updated STS101 Development Plan

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-